Cargando…

Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis

CONTEXT: Body mass index (BMI) is a useful tool for measuring body composition. It is unclear whether high BMI is a favourable indicator in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). OBJECTIVE: To investigate the prognostic significance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takemura, Kosuke, Yonekura, Satoru, Downey, Laura E., Evangelopoulos, Dimitris, Heng, Daniel Y.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Kidney Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068728/ https://www.ncbi.nlm.nih.gov/pubmed/35528786 http://dx.doi.org/10.1016/j.euros.2022.03.002

Ejemplares similares

Impact of Body Mass Index on Survival of Metastatic Renal Cancer
por: Plonski, Jose Javier Salgado, et al.
Publicado: (2021)

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era
por: Shah, Neil J., et al.
Publicado: (2023)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
por: Bosma, Nicholas A., et al.
Publicado: (2022)

RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned
por: Agarwal, Dinesh K., et al.
Publicado: (2023)

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023)

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary Kidney
por: Attawettayanon, Worapat, et al.
Publicado: (2023)

Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative
por: Patel, Amit K., et al.
Publicado: (2021)

Initial Observation of a Large Proportion of Patients Presenting with Clinical Stage T1 Renal Masses: Results from the MUSIC-KIDNEY Statewide Collaborative
por: Patel, Amit K., et al.
Publicado: (2020)

New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study
por: Pecoraro, Alessio, et al.
Publicado: (2023)

Randomized Clinical Trial Comparing On-clamp Versus Off-clamp Laparoscopic Partial Nephrectomy for Small Renal Masses (CLOCK II Laparoscopic Study): A Intention-to-treat Analysis of Perioperative Outcomes
por: Bertolo, Riccardo, et al.
Publicado: (2022)

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology
por: Kang, Cyra Y, et al.
Publicado: (2022)

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
por: Gulati, Sakshi, et al.
Publicado: (2014)

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma
por: Staehler, Michael, et al.
Publicado: (2021)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
por: Almdalal, Tarik, et al.
Publicado: (2022)

Estimated Glomerular Filtration Rate Decline at 1 Year After Minimally Invasive Partial Nephrectomy: A Multimodel Comparison of Predictors
por: Crocerossa, Fabio, et al.
Publicado: (2022)

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Impact of Positive Surgical Margins After Partial Nephrectomy
por: Carvalho, João André Mendes, et al.
Publicado: (2020)

Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma
por: Davidsson, Sabina, et al.
Publicado: (2020)

In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on (99m)Tc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination
por: Papathomas, Thomas, et al.
Publicado: (2020)

Risk Prediction Models for Kidney Cancer: A Systematic Review
por: Harrison, Hannah, et al.
Publicado: (2021)

Outcomes for Atypical Tumor Recurrences Following Minimally Invasive Kidney Cancer Operations
por: Russo, Paul, et al.
Publicado: (2022)

Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2022)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
por: Marconi, Lorenzo, et al.
Publicado: (2022)

Association of Artificially Sweetened Beverage Consumption and Urinary Tract Cancers in the Women’s Health Initiative Observational Study
por: Ringel, Nancy E., et al.
Publicado: (2022)

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2022)

Impact of Surgical Experience Before Robot-assisted Partial Nephrectomy on Surgical Outcomes: A Multicenter Analysis of 2500 Patients
por: Harke, Nina N., et al.
Publicado: (2022)

Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions
por: Patel, Hiten D., et al.
Publicado: (2022)

Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell Carcinoma
por: Tanaka, Hajime, et al.
Publicado: (2022)

Impact of Partial Nephrectomy and Percutaneous Cryoablation on Short-term Health-related Quality of Life—A Prospective Comparative Cohort Study
por: Junker, Theresa, et al.
Publicado: (2022)

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
por: Fransen van de Putte, Elisabeth E., et al.
Publicado: (2023)

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
por: Piccinelli, Mattia L., et al.
Publicado: (2023)

Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy
por: Abdelsalam, Mohamed E., et al.
Publicado: (2023)

Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models
por: Ouzaid, Idir, et al.
Publicado: (2022)

Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy
por: Drobner, Jake, et al.
Publicado: (2023)

Current markers and their value in the era of immuno-oncology
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2017)

A perspective on HPK1 as a novel immuno-oncology drug target
por: Sawasdikosol, Sansana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ksgrlsc9e9bu8gh3t5ctd9d2l